Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, announces the publication of a paper entitled “Alpha-synuclein, the culprit in Parkinson's Disease, is required for normal immune function.”, mehr …
nowmag.de/content/34405/enterin-and-their-collaborators-at-nih-announce-that-alpha-synuclein-the-culprit-in-parkinson-und-apos-s-disease-is-core-and-central-to-normal-immune-function.html
Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson’s Disease
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced that it will host a webinar to present top-line results from the Phase 2b (KARMET) study in patients with Parkinson’s disease on Thursday, Jan. 27 at 2:30 pm EST, mehr …
nowmag.de/content/35483/enterin-to-announce-top-line-results-from-the-phase-2b-study-for-parkinsons-disease.html
“The Batman” Debuts In The Visually Immersive 270 Degree Panoramic ScreenX Theater
Also Experience the Film in CJ 4DPLEX’s Multi-Sensory 4DX Theaters.te, mehr …
nowmag.de/content/38531/the-batman-debuts-in-the-visually-immersive-270-degree-panoramic-screenx-theater.html
